Hotspot cleared to enter clinic with small-molecule allosteric CBL-B inhibitor HST-1011 for solid tumors
Jan. 4, 2023
Hotspot Therapeutics Inc. has received FDA clearance of its IND application for HST-1011, the company's investigational small-molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B), an E3 ubiquitin protein ligase critically involved in immune cell response.